In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls
- PMID: 35455402
- PMCID: PMC9032852
- DOI: 10.3390/ph15040405
In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls
Abstract
Major depressive disorder and major depressive episodes (MDD/MDE) are characterized by the activation of the immune-inflammatory response system (IRS) and the compensatory immune-regulatory system (CIRS). Cannabidiol (CBD) is a phytocannabinoid isolated from the cannabis plant, which is reported to have antidepressant-like and anti-inflammatory effects. The aim of the present study is to examine the effects of CBD on IRS, CIRS, M1, T helper (Th)-1, Th-2, Th-17, T regulatory (Treg) profiles, and growth factors in depression and healthy controls. Culture supernatant of stimulated (5 μg/mL of PHA and 25 μg/mL of LPS) whole blood of 30 depressed patients and 20 controls was assayed for cytokines using the LUMINEX assay. The effects of three CBD concentrations (0.1 µg/mL, 1 µg/mL, and 10 µg/mL) were examined. Depression was characterized by significantly increased PHA + LPS-stimulated Th-1, Th-2, Th-17, Treg, IRS, CIRS, and neurotoxicity profiles. CBD 0.1 µg/mL did not have any immune effects. CBD 1.0 µg/mL decreased CIRS activities but increased growth factor production, while CBD 10.0 µg/mL suppressed Th-1, Th-17, IRS, CIRS, and a neurotoxicity profile and enhanced T cell growth and growth factor production. CBD 1.0 to 10.0 µg/mL dose-dependently decreased sIL-1RA, IL-8, IL-9, IL-10, IL-13, CCL11, G-CSF, IFN-γ, CCL2, CCL4, and CCL5, and increased IL-1β, IL-4, IL-15, IL-17, GM-CSF, TNF-α, FGF, and VEGF. In summary, in this experiment, there was no beneficial effect of CBD on the activated immune profile of depression and higher CBD concentrations can worsen inflammatory processes.
Keywords: biomarkers; cytokines; depression; inflammation; mood disorders; neuroimmunomodulation; psychiatry.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach.Cells. 2022 Mar 31;11(7):1183. doi: 10.3390/cells11071183. Cells. 2022. PMID: 35406747 Free PMC article.
-
T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors.J Adv Res. 2024 Oct;64:171-181. doi: 10.1016/j.jare.2023.11.012. Epub 2023 Nov 13. J Adv Res. 2024. PMID: 37967811 Free PMC article.
-
Evaluation of Inflammatory Response System (IRS) and Compensatory Immune Response System (CIRS) in Adolescent Major Depression.J Inflamm Res. 2022 Oct 26;15:5959-5976. doi: 10.2147/JIR.S387588. eCollection 2022. J Inflamm Res. 2022. PMID: 36303711 Free PMC article.
-
The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder.Mol Neurobiol. 2018 Dec;55(12):8885-8903. doi: 10.1007/s12035-018-1016-x. Epub 2018 Apr 2. Mol Neurobiol. 2018. PMID: 29611101 Review.
-
The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia.Mol Neurobiol. 2020 Feb;57(2):778-797. doi: 10.1007/s12035-019-01737-z. Epub 2019 Aug 31. Mol Neurobiol. 2020. PMID: 31473906 Review.
Cited by
-
The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach.Cells. 2022 Mar 31;11(7):1183. doi: 10.3390/cells11071183. Cells. 2022. PMID: 35406747 Free PMC article.
-
Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles.Cells. 2022 May 7;11(9):1564. doi: 10.3390/cells11091564. Cells. 2022. PMID: 35563878 Free PMC article.
-
T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors.J Adv Res. 2024 Oct;64:171-181. doi: 10.1016/j.jare.2023.11.012. Epub 2023 Nov 13. J Adv Res. 2024. PMID: 37967811 Free PMC article.
-
In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity.Sci Rep. 2024 Mar 28;14(1):7344. doi: 10.1038/s41598-024-57350-1. Sci Rep. 2024. PMID: 38538641 Free PMC article.
-
Immune cell exhaustion and apoptotic markers in major depressive disorder: Effects of in vitro cannabidiol administration.Brain Behav Immun Health. 2025 Jul 19;48:101066. doi: 10.1016/j.bbih.2025.101066. eCollection 2025 Oct. Brain Behav Immun Health. 2025. PMID: 40735287 Free PMC article.
References
-
- Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012;36:764–785. doi: 10.1016/j.neubiorev.2011.12.005. - DOI - PubMed
-
- Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: Inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology. 2012;20:127–150. doi: 10.1007/s10787-011-0111-7. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources